RU95119831A - RISPERIDONPMOAT - Google Patents

RISPERIDONPMOAT

Info

Publication number
RU95119831A
RU95119831A RU95119831/04A RU95119831A RU95119831A RU 95119831 A RU95119831 A RU 95119831A RU 95119831/04 A RU95119831/04 A RU 95119831/04A RU 95119831 A RU95119831 A RU 95119831A RU 95119831 A RU95119831 A RU 95119831A
Authority
RU
Russia
Prior art keywords
composition according
compound according
compound
composition
risperidone
Prior art date
Application number
RU95119831/04A
Other languages
Russian (ru)
Other versions
RU2131428C1 (en
Inventor
Луи Месенс Жан
Пэтерс Йозеф
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Priority claimed from PCT/EP1994/001296 external-priority patent/WO1994025460A1/en
Publication of RU95119831A publication Critical patent/RU95119831A/en
Application granted granted Critical
Publication of RU2131428C1 publication Critical patent/RU2131428C1/en

Links

Claims (1)

1. Соединение, являющееся солью присоединения памоиновой кислоты к рисперидону.1. A compound that is a salt of addition of pamoic acid to risperidone. 2. Рисперидонпамоат по п. 1 формулы I
Figure 00000001

3. Композиция, содержащая фармацевтически приемлемый носитель и в качестве активного средства фармацевтически эффективное количество соединения по п. 1.2. Risperidone according to claim 1 of formula I
Figure 00000001

3. A composition comprising a pharmaceutically acceptable carrier and, as an active agent, a pharmaceutically effective amount of a compound according to claim 1. 4. Композиция по п. 3 в лекарственной форме, пригодной для инъекций. 4. The composition according to claim 3 in a dosage form suitable for injection. 5. Композиция по п. 4 в виде водной суспензии. 5. The composition according to p. 4 in the form of an aqueous suspension. 6. Композиция по п. 5, дополнительно содержащая бензиловый спирт, сложный эфир сорбитана и воду. 6. The composition according to claim 5, further comprising benzyl alcohol, sorbitan ester and water. 7. Композиция по п. 6, дополнительно содержащая производное целлюлозы. 7. The composition according to p. 6, optionally containing a derivative of cellulose. 8. Способ получения композиции по п. 3, отличающийся тем, что фармацевтически эффективное количество соединения по п. 1 тщательно смешивают с фармацевтически приемлемым носителем. 8. The method for preparing the composition according to claim 3, wherein the pharmaceutically effective amount of the compound according to claim 1 is thoroughly mixed with a pharmaceutically acceptable carrier. 9. Соединение по п. 1 в качестве лекарственного средства. 9. The compound according to claim 1 as a drug. 10. Способ получения соединения по п. 1, отличающийся тем, что 3-/2-/4-(6-фтор-1,2-бензизоксазол-3-ил)-1-пиперидинил/этил/-6,7,8,9- тетрагидро-2-метил-4Н-пиридо/1,2-а/пиримидин-4-он обрабатывают памоиновой кислотой в инертном растворителе. 10. A method of producing a compound according to claim 1, wherein 3- / 2- / 4- (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl / ethyl / -6,7,8 , 9-tetrahydro-2-methyl-4H-pyrido / 1,2-a / pyrimidin-4-one is treated with pamoic acid in an inert solvent.
RU95119831A 1993-04-28 1994-04-22 Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing RU2131428C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93201216.4 1993-04-28
EP93201216 1993-04-28
PCT/EP1994/001296 WO1994025460A1 (en) 1993-04-28 1994-04-22 Risperidone pamoate

Publications (2)

Publication Number Publication Date
RU95119831A true RU95119831A (en) 1997-11-10
RU2131428C1 RU2131428C1 (en) 1999-06-10

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95119831A RU2131428C1 (en) 1993-04-28 1994-04-22 Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing

Country Status (32)

Country Link
US (2) US5612346A (en)
EP (1) EP0697019B1 (en)
JP (1) JP3478397B2 (en)
KR (1) KR100307101B1 (en)
CN (1) CN1041727C (en)
AT (1) ATE163418T1 (en)
AU (1) AU675136B2 (en)
BG (1) BG62004B1 (en)
CA (1) CA2160366C (en)
CY (1) CY2107B1 (en)
CZ (1) CZ286688B6 (en)
DE (1) DE69408666T2 (en)
DK (1) DK0697019T3 (en)
ES (1) ES2113652T3 (en)
FI (1) FI109125B (en)
GR (1) GR3026028T3 (en)
HK (1) HK1006059A1 (en)
HU (1) HU218212B (en)
IL (1) IL109448A (en)
LV (1) LV12315B (en)
NO (1) NO305083B1 (en)
NZ (1) NZ266143A (en)
PH (1) PH30476A (en)
PL (1) PL182466B1 (en)
RO (1) RO115955B1 (en)
RU (1) RU2131428C1 (en)
SG (1) SG47046A1 (en)
SI (1) SI9420031B (en)
SK (1) SK280589B6 (en)
TW (1) TW376319B (en)
WO (1) WO1994025460A1 (en)
ZA (1) ZA942909B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219487B (en) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Microparticles containing risperidone, process for producing them, their use, medicaments containing the same and their production
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
KR100537713B1 (en) * 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-Methyl-Thieno-Benzodiazepine Formulation
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (en) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
TR200100885T2 (en) * 1998-09-30 2001-08-21 Eli Lilly And Company 2-Methyl-thieno-benzodiazepine formulation
CA2349700A1 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (en) 1999-12-10 2003-02-28 Aventis Pharma Sa COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534288A1 (en) * 2002-08-23 2005-06-01 Ranbaxy Laboratories, Ltd. Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (en) * 2002-10-18 2004-04-29 한미약품 주식회사 Improved method for the preparation of risperidone
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
DK1675573T4 (en) * 2003-10-23 2012-08-06 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245617A1 (en) * 2004-01-29 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of CNS-related conditions
WO2006073886A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (en) * 2005-07-28 2007-08-08 Alza Corp LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
JP4879349B2 (en) * 2007-07-31 2012-02-22 大塚製薬株式会社 Method for producing aripiprazole suspension and lyophilized preparation
RS61765B1 (en) * 2007-12-19 2021-05-31 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
SI3156056T1 (en) 2011-03-18 2024-03-29 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US9040695B2 (en) * 2011-04-26 2015-05-26 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
JP6333802B2 (en) * 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising benzyl alcohol
CA2868381C (en) 2012-04-04 2020-07-07 Intervet International B.V. Soft chewable pharmaceutical products
CN102659577B (en) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 Preparation method of pamoic acid
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
EP2900270B1 (en) 2012-09-26 2019-03-06 Tangent Reprofiling Limited Combination of benzo(iso)oxazolepiperidines with conjugated linoleic acid
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
RU2688233C2 (en) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Aripiprazole preparations having high injection rates
CN106831594B (en) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 Clonidine embonate and preparation method thereof
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Similar Documents

Publication Publication Date Title
RU95119831A (en) RISPERIDONPMOAT
JP2744057B2 (en) Combination of pyrimidine and salicylic acid derivatives for inducing and stimulating hair growth and reducing hair loss
CA2011532C (en) Formulation
RU2131428C1 (en) Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing
RU95118439A (en) IMIDAZOPIRIDINE AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD FOR ITS PRODUCTION
RU95121639A (en) AZA Cyclohexappeptide Compounds
CA2284977A1 (en) 3,3-disubstituted propylamines, their use and preparation
ATE143368T1 (en) WATER SOLUBLE CAMPTOTHECIN ANALOGUES
RU2006101999A (en) MEANS FOR THE TREATMENT OF SCHIZOPHRENIA BASED ON HYDROGEN PYRIDO (4,3-B) INDOLES (OPTIONS), PHARMACOLOGICAL PRODUCT ON ITS BASIS AND METHOD OF ITS APPLICATION
RU2006142521A (en) MEANS FOR IMPROVING COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDROGEN PYRIDO (4,3-B) INDOLES (OPTIONS), PHARMACOLOGICAL PRODUCT ON ITS BASIS AND METHOD OF ITS APPLICATION
NO940523L (en) New pyrazine derivatives
US5665384A (en) Oily capsules of ketoprofen
RU2007114948A (en) PHARMACEUTICAL COMPOSITION CONTAINING THEMZOLOMIDE ETHER
RU96119364A (en) DERIVATIVE BENZAMIDE, COMPOSITIONS CONTAINING SUPERIOR DERIVATIVE, AND THEIR APPLICATION
ATE55248T1 (en) DRUG COMBINATION.
IL83086A (en) Stable,injectable solutions of vincristine salts
JPH11189531A (en) Pharmaceutical composition for transmucosal administration
KR880004810A (en) Peptic Ulcer Treatment
US3849558A (en) Pharmaceutical compositions having controlled gastro-intestinal absorption
ES8106517A1 (en) 10-halo-E-homoeburnane derivatives, a process for the preparation thereof, a process for the use thereof as vasodilators, and vasodilating compositions thereof
RU95119815A (en) AGENT, ACTING ON THE CENTRAL NERVOUS SYSTEM, METHOD FOR ITS OBTAINING AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
TH12553B (en) Risperidone Pamoet
SI9300150B (en) Endo-2,3-dihydro-n-(8-methyl-8-azabicyclo(3.2.1) okt-3-yl)-2-oxo-1h- benzimidazol-1-carboxamid hydrochlorid monohydrate and endo-3-ethyl- 2,3-dihydro-n-(8-methyl-8-azabicyclo-(3.2.1) okt-3-yl)-2-oxo-1h- benzimidazole-1-carboxamid hydrochlorid monohydrate christal forms
IE872678L (en) IMIDAZO 4,5-b PYRIDIN-2-ONE DERIVATIVES, THEIR PREPARATION¹AND COMPOSITIONS CONTAINING THEM
RU2002115270A (en) Compounds and method for treating pain